Trials / Active Not Recruiting
Active Not RecruitingNCT06596642
A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan
Taiwan β-Thalassemia Major Real-World Study for Luspatercept
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 61 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This real-world study will assess the efficacy and safety of luspatercept treatment for β-thalassemia major in Taiwan as well as the impact on quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Luspatercept | As per product label |
Timeline
- Start date
- 2024-08-21
- Primary completion
- 2026-10-01
- Completion
- 2026-12-17
- First posted
- 2024-09-19
- Last updated
- 2025-06-04
Locations
5 sites across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06596642. Inclusion in this directory is not an endorsement.